^
    Back
    Association details:
    Biomarker:CDK12 mutation
    Cancer:Prostate Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

    Excerpt:
    Inactivating mutation (at least monoallelic of CDK12) by clinical grade testing
    Trial ID:
    NCT04019964
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JCO Precis Oncol
    Title:

    CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

    Published date:
    04/21/2020
    Excerpt:
    Nine men received a PD-1 inhibitor as fourth- to sixth-line systemic therapy (pembrolizumab [n = 5], nivolumab [n = 4]); 33.3% had a PSA response, and median PFS was 5.4 months….some patients with CDK12-altered mCRPC may have favorable responses to PD-1 inhibitor agents..
    DOI:
    10.1200/PO.19.00399